WNAM MONITORING: President Shavkat Mirziyoyev got acquainted with the work results and long-term plans in pharmaceuticals.
This industry, which is essential for the economy and healthcare, is given special attention, and the necessary legal and organizational conditions are created. Only at the beginning of this year two documents in this direction were adopted. In particular, in accordance with the Presidential Resolution of January 10, a roadmap for 2024-2025 was approved for the development of the pharmaceutical industry and the acceleration of investment projects. The decree adopted on January 23 defines additional measures to regulate the pharmaceutical sector.
$100 million in low-cost resources has been allocated for new industry projects. In addition, Asakabank raised $200 million.
As a result of these opportunities, two projects worth $30.5 million have been launched over the past four months, creating 160 jobs. Products worth 1.5 trillion UZS were produced, and exports worth $51 million were carried out.
However, these results are still insufficient. There is an enormous untapped potential. In particular, this year it is planned to manufacture products worth $400 million and increase exports to $200 million. 147 projects worth $2 billion are scheduled to begin, of which 28 will be commissioned this year. It is planned to localize 450 new types of products.
The Head of state emphasized the need to increase the saturation level of domestic products in the domestic market.
Particular attention was paid to transitioning production to international standards and ensuring a balance between price and quality. To this end, the goal has been set to bring digitalization in the industry to 65 percent this year and fully complete it next year. It was noted that this will reduce prices by at least 20 percent.
Measures to intensify the activities of the innovative pharmaceutical cluster “Tashkent Pharma Park” and launch 12 projects worth $470 million were discussed.
Information was also provided on attracting investors to the pharmaceutical industry and increasing the number of new projects.
